Cohort Study of Patients With Type 1 Diabetes
2 juillet 2022 mis à jour par: Zhiguang Zhou, Second Xiangya Hospital of Central South University
Cohort Study of Patients With Type 1 Diabetes：Clarifing the Underlying Hereditary and Autoimmune Pathogenic Factors
This study aims to clarify the underlying hereditary and autoimmune factors that contribute to clinical type 1 diabetes and gain a better understanding of the natural history of the disease.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Observationnel
Inscription (Réel)
2110
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Hunan
-
Changsha, Hunan, Chine, 410011
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
type 1 diabetes patients
La description
Inclusion Criteria:
- diabetes diagnosed according to the report of WHO (World Health Organization) in 1999;
- insulin dependence from disease onset,thus diagnosed with type 1 diabetes;
- all patients gave informed consent to participate in the study and the protocol was approved by the Research Ethics Committee in second Xiangya hospital, Central South University.
Exclusion Criteria:
- secondary diabetes mellitus;
- pregnant women;
- malignant disease.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Intensive structured education group
Regular outpatient visit in every 3 months to these patients.
The glucose control and diabetes complication screening will be evaluated in visit.
Patients will also be evaluated by specialized psychologists, dietitians and therapists.
Diabetes self-management education will be regularly exposed to patients
|
The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
|
|
Conventional education group
Outpatients visit to endocrinologists when necessary in a conventional way.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effects of structured education on β-cell endocrine function progression of T1D patients.
Délai: Baseline and every three months afterwards.
|
The natural progression of patients' β-cell endocrine functions was assessed by fasting C-peptide (FCP) and postprandial C-peptide (PCP) at each visit. FCP and PCP levels were measured at initial recruitment and every three months after that. The decay rate of β-cell endocrine function of patients in the two groups were compared. Serum C-peptide levels were measured by a chemiluminescence method using a commercial available kit (Adiva Centaur System, Siemens, Germany). |
Baseline and every three months afterwards.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effects of structured education on blood sugar control.
Délai: Baseline and every three months afterwards.
|
Patients' daily insulin dosage (U/Day) were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.
|
Baseline and every three months afterwards.
|
|
Effects of structured education on blood sugar control.
Délai: Baseline and every three months afterwards.
|
Patients' blood sugar levels were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.
|
Baseline and every three months afterwards.
|
|
Effects of structured education on blood sugar control.
Délai: Baseline and every three months afterwards.
|
Patients' HbA1c levels were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.HbA1c concentration was tested by the Bio-Red Variant automatic measurement system.
|
Baseline and every three months afterwards.
|
|
Effects of structured education on metabolic control.
Délai: Baseline and every three months afterwards.
|
Patients' body mass index (BMI) levels were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.
|
Baseline and every three months afterwards.
|
|
Effects of structured education on metabolic control.
Délai: Baseline and every three months afterwards.
|
Patients' systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.
|
Baseline and every three months afterwards.
|
|
Effects of structured education on metabolic control.
Délai: Baseline and every three months afterwards.
|
Patients' triglyceride (TG) and total cholesterol (TC) levels were collected at initial recruitment and each visit afterwards.
And the above mentioned parameters in group 1(patients with structured education) and group2(patients without structured education) were compared.
|
Baseline and every three months afterwards.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Chen Y, Xia Y, Xie Z, Zhong T, Tang R, Li X, Zhou Z. The Unfavorable Impact of DR9/DR9 Genotype on the Frequency and Quality of Partial Remission in Type 1 Diabetes. J Clin Endocrinol Metab. 2022 Jan 1;107(1):e293-e302. doi: 10.1210/clinem/dgab589.
- Zhu S, Liu F, Li J, Guan Y, Meng M, Li X, Zhou Z, Xu R, Li L. Development and validation of a self-management scale of type 1 diabetes for Chinese adults. J Int Med Res. 2020 Aug;48(8):300060520947588. doi: 10.1177/0300060520947588.
- Li X, Zhong T, Tang R, Wu C, Xie Y, Liu F, Zhou Z. PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes. J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgaa130. doi: 10.1210/clinem/dgaa130.
- Xie Y, Liu F, Huang F, Lan C, Guo J, He J, Li L, Li X, Zhou Z. Establishment of a type 1 diabetes structured education programme suitable for Chinese patients: type 1 diabetes education in lifestyle and self adjustment (TELSA). BMC Endocr Disord. 2020 Mar 10;20(1):37. doi: 10.1186/s12902-020-0514-9.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 octobre 2016
Achèvement primaire (Réel)
31 décembre 2021
Achèvement de l'étude (Réel)
31 décembre 2021
Dates d'inscription aux études
Première soumission
11 mai 2018
Première soumission répondant aux critères de contrôle qualité
25 juillet 2018
Première publication (Réel)
2 août 2018
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
6 juillet 2022
Dernière mise à jour soumise répondant aux critères de contrôle qualité
2 juillet 2022
Dernière vérification
1 juillet 2022
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- T1D Cohort Study
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .